Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14388170 | 0.87 | CYP2D6 (0.56) | ALDH1A1CYP2D6SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL8434176 | 0.83 | CYP2D6 (0.62) | ALDH1A1CYP2D6SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL17683026 | 0.79 | CYP2D6 (0.43) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL8436912 | 0.79 | KDM4E (0.46) | ALDH1A1CYP2D6SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL8436838 | 0.78 | SMN1; SMN2 (0.36) | ALDH1A1CYP2D6SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL12030770 | 0.78 | ALDH1A1 (0.42) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL8259518 | 0.75 | ALDH1A1 (0.40) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL12258804 | 0.74 | ALDH1A1 (0.51) | ALDH1A1CYP2D6SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL12870586 | 0.72 | ALDH1A1 (0.50) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL8193648 | 0.72 | ALDH1A1 (0.50) | ALDH1A1CYP2D6SMN1; SMN2KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329658-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2008-02-12 | — | — | US | disclosed |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | ALDH1A1 1683/4885CYP2D6 1363/4885SMN1; SMN2 3678/4885 |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | ALDH1A1 1926/4885CYP2D6 1404/4885SMN1; SMN2 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.